Vanguard Portfolio Management
FULC icon

Vanguard Portfolio Management’s Fulcrum Therapeutics FULC Stock Holding History

Vanguard Portfolio Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.86M Buy
782,144
+182,765
+30% +$1.11M ﹤0.01% 2620
2026
Q1 		$4.6M Buy
+599,379
New +$5.56M ﹤0.01% 2345

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management's FULC Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Fulcrum Therapeutics (FULC) stake by 30% in Q2 2026, buying an estimated $1.11M and bringing the position to 782,144 shares worth $2.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2620.

Vanguard Portfolio Management first reported a position in FULC in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.6M in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Vanguard Portfolio Management held 782,144 shares of Fulcrum Therapeutics worth $2.86M as of Q2 2026.
  • Vanguard Portfolio Management bought 182,765 Fulcrum Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Fulcrum Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2620 holding.
  • Vanguard Portfolio Management first reported a position in Fulcrum Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's Fulcrum Therapeutics position peaked at $4.6M in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.